Influenza

Antibody Response to Egg- and Cell-Grown Influenza A

By

Bradley van Paridon

Adults who received the flu vaccine in 2017 to 2018 had higher antibody titers against the egg-adapted vaccine and lower titers against circulating virus.

The CDC Estimates 2018-2019 Seasonal Influenza Vaccine Effectiveness

By

Pulmonology Advisor Contributing Writer

Influenza vaccine efficacy, between November 23, 2018 and February 2, 2019, was 47% overall and 61% for young children.

FDA to Review Baloxavir Marboxil sNDA for Flu in Patients at High Risk for Complications

By

Steve Duffy Digital Content Editor

The FDA has accepted for review the sNDA for for Xofluza for the treatment of influenza in patients at high risk of complications.

Oseltamivir Effective in Critically Ill Patients With Influenza A/H3N2

By

Pulmonology Advisor Contributing Writer

Oseltamivir should be administered to treat critically ill individuals with influenza, particularly when A/H3N2 is circulating.

Antiviral Agents Compared for Treatment of Influenza

By

Da Hee Han, PharmD

In otherwise healthy patients, influenza treatment with baloxavir marboxil was found to be comparable, and on some efficacy measures, superior to neuraminidase inhibitors.

Analysis of Rapid Molecular Influenza Tests Are Heterogeneous

By

Zahra Masoud

Rapid molecular tests for viral pathogen detection provide accurate results and implementation in hospital settings is recommended.

Measuring Influenza Vaccine Responses of Pregnant Women With and Without HIV

By

Pulmonology Advisor Contributing Writer

Tafenoquine has performed comparably with primaquine in terms of hemoglobin level decrease in individuals with malaria and normal glucose-6-phosphate dehydrogenase enzyme levels.

New Dosing Option for Fluzone Quadrivalent in Children as Young as 6 Months

By

DaHee Han PharmD

The approval was based on findings from a Phase 4 safety and immunogenicity study that included ~2000 children.